Appendix A – search strategies

#	Medline Search Terms
	Patient-reported outcome terms
1	patient reported outcome*.tw.
2	"Quality of Life"/
3	(qualit* adj2 life).tw.
4	self report/
5	((self or patient) adj1 report*).tw.
6	health status/
7	health status.tw.
8	(health adj2 level*).tw.
9	data collection/st [standards]
	Missing data terms
10	missing data.tw.
11	missing value*.tw.
12	missing response*.tw.
13	missing item*.tw.
14	(compliance adj3 ('quality of life' or 'patient reported outcome*' or QOL or QL or HRQOL or HRQL or PRO)).tw.
15	(response rate adj1 ('quality of life' or 'patient reported outcome*' or QOL or QL or HRQOL or HRQL or PRO)).tw.
16	completion rate*.tw.
17	attrition.tw.
18	drop out.tw.
19	los* to follow up.tw.
20	quality assurance.tw.
21	quality control.tw.
22	"missing patient-reported outcome* data".tw.
23	"missing quality of life data".tw.
24	"missing PRO data".tw.
25	"missing QOL data".tw.
26	"missing QL data".tw.
27	"missing HRQOL data".tw.
28	"missing HRQL data".tw.
	Combination
29	or/1-9
30	or/10-28
31	29 and 30
32	limit 31 to English language

Search ID#	CINAHL Search Terms
S1	(MH "Outcome Assessment")
S2	TI quality of life OR AB quality of life
S3	(MH "Quality of Life+")
S4	TI Self-report* or AB Self-report*
S5	(MH "Self Report")
S6	TI patient-report* or AB patient-report*
S7	TI health status OR AB health status
S8	(MH "Health Status+")
S9	TI health level OR AB health level
S10	TI level of health OR AB level of health
S11	TI missing data OR AB missing data
S12	TI missing value* OR AB missing value*
S13	TI missing response* OR AB missing response*
S14	TI missing item* OR AB missing item*
S15	TI completion rate* OR AB completion rate*
S16	TI attrition OR AB attrition
S17	TI drop out OR AB drop out
S18	TI los* to follow up OR AB los* to follow up
S19	TI quality assurance OR AB quality assurance
S20	TI quality control OR AB quality control
S21	TI “missing patient-reported outcome* data” OR AB “missing patient-reported outcome* data”
S22	TI "missing quality of life data" OR AB" missing quality of life data"
S23	TI "missing PRO data" OR AB "missing PRO data"
S24	TI "missing QOL data" OR AB "missing QOL data"
S25	TI "missing QL data" OR AB "missing QL data"
S26	TI "missing HRQOL data" OR AB "missing HRQOL data"
S27	TI "missing HRQL data" OR AB "missing HRQL data"
S28	S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10
S29	S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27
S30	S28 AND S29

Appendix B – PRISMA checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	1-2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	3
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5-6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Supp. Material (A1)
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5-6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	6

Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	N/A, see p8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2 for each meta-analysis.)	6
Risk of bias across studies	15	N/A	N/A see pgs 6 & 8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	N/A
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	Figure 1
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Table 1, pp6-7
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	N/A see pgs 6 & 8
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	N/A
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	Pp 6-7, 11-49
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	N/A
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	8
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	9
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	10
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	11

Appendix C – Included sources

1 Aaronson NK. Quality of life research in cancer clinical trials: a need for common rules and language. Oncology (Williston). 1990;4(5):59-66.

2 Altman DG, Bland JM. Missing data. Bmj. 2007;334(7590):424

3 Altman, D. G. Practical Statistics for Medical Research, Chapman and Hall, London, 1993.

4 Atherton PJ, Novotny PJ, Tan AD. Analyzing the "correct" endpoint. Curr Probl Cancer. 2006;30(6):283-97. Epub 2006/11/25.

5 Bakitas M, Lyons, K. D., M. T. Hegel, et al. (2009). "The project ENABLE II randomized controlled trial to improve palliative care for rural patients with advanced cancer: baseline findings, methodological challenges, and solutions." Palliative & Supportive Care 7(1): 75-86.

6 Basch E. New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med. 2014;65:307-17.

7 Basch et al. Recommendations for Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research in Adult Oncology. JCO 2012, 30 (34) 4249-4255

8 Beitz J, Gnecco C, Justice R. Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr. 1996;Monographs.(20):7-9

9 Bell ML, Fairclough DL. Practical and statistical issues in missing data for longitudinal patient-reported outcomes. Stat Methods Med Res. 2014;23(5):440-59.

10 Bell ML, Olivier J, King MT. Scientific rigour in psycho-oncology trials: why and how to avoid common statistical errors. Psychooncology. 2013; 22: 499-505. doi: 410.1002/pon.3046.

11 Bernhard J, Cella DF, Coates AS, et al. Missing quality of life data in cancer clinical trials: serious problems and challenges. Statistics in Medicine. 1998; 17 (5-7):517-32.

12 Bernhard J, Gusset H, Hurny C. Practical issues in quality of life assessment in multicentre trials conducted by the Swiss Group for Clinical Cancer Research. Stat Med. 1998;17(5-7):633-9.

13 Bernhard J, Peterson HF, Coates AS, Gusset H, Isley M, Hinkle R, et al. Quality of life assessment in International Breast Cancer Study Group (IBCSG) trials: practical issues and factors associated with missing data. Stat Med. 1998;17(5-7):587-601.

14 BIQSFP. Biomarker, Imaging, and Quality of Life Studies Funding Program) Quality of Life Study Evaluation Guidelines. 2012 [27/02/2013]; Available from: http://www.cancer.gov/aboutnci/organization/ccct/funding/BIQSFP/BIQSFP-12-QOL-Study-Evaluation-Guidelines

15 Blazeby JM, Nicklin J, Brookes ST, Winstone K, Alderson D. Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer. Br J Cancer. 2003;89(3):497-501.

16 Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD. Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. Jama. 2013;309(8):814-22.

17 Calvert MJ, Freemantle N. Use of health-related quality of life in prescribing research. Part 2: methodological considerations for the assessment of health-related quality of life in clinical trials. J Clin Pharm Ther. 2004; 29: 85-94.

18 Cantrell MA, Lupinacci P. Methodological issues in online data collection. J Adv Nurs. 2007;60(5):544-9

19 Cella DF, Lloyd SR. Data collection strategies for patient-reported information. Qual Manag Health Care. 1994;2(4):28-35.

20 Cella, D. F. (1995). "Methods and problems in measuring quality of life." Supportive Care in Cancer 3(1): 11-22.

21 Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N, for the European Regulatory Issues on Quality of Life Assessment Group. Patient-Reported Outcomes: The Example of Health-Related Quality of Life—A European Guidance Document for the Improved Integration of Health-Related Quality of Life Assessment in the Drug Regulatory Process. Drug Inf J. 2002;36(1):209-38

22 Coates A, Gebski V. Quality of life studies of the Australian New Zealand Breast Cancer Trials Group: approaches to missing data. Stat Med. 1998;17(5-7):533-40.
23 Conroy T, Bleiberg H, Glimelius B. Quality of life in patients with advanced colorectal cancer: what has been learnt? Eur J Cancer. 2003;39(3):287-94.
24 Curran D, Bacchi M, Schmitz SF, Molenberghs G, Sylvester RJ. Identifying the types of missingness in quality of life data from clinical trials. Stat Med. 1998;17(5-7):739-56
25 Davies AR, Doyle MA, Lansky D, Rutt W, Orsolits Stevic M, Doyle JB. Outcomes assessment in clinical settings: a consensus statement on principles and best practices in project management. Jt Comm J Qual Improv. 1994;20(1):6-16.
26 Deo A, Schmid CH, Earley A, Lau J, Uhlig K. Loss to Analysis in Randomized Controlled Trials in CKD. American Journal of Kidney Diseases. 2011;58(3):349-55.
27 Dumville JC, Torgerson DJ, Hewitt CE. Reporting attrition in randomised controlled trials. BMJ (Clinical research ed). 2006;332(7547):969-71.
28 Dunn KM, Jordan K, Croft PR. Does questionnaire structure influence response in postal surveys? J Clin Epidemiol. 2003;56(1):10-6.
29 Dykema, J., J. Stevenson, et al. (2012). "Use of Monetary and Nonmonetary Incentives to Increase Response Rates Among African Americans in the Wisconsin Pregnancy Risk Assessment Monitoring System." Maternal & Child Health Journal 16(4): 785-791
30 Fairclough D. (2010) Design and Analysis of Quality of Life Studies in Clinical Trials, 2nd Edition. New York: Chapman & Hall.
31 Fallowfield L. Compliance issues in quality of life assessment: experiences of two Cancer Research Campaign sponsored groups. Stat Med. 1998;17(5-7):541-6.
32 Fallowfield LJ, Harper P. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer. 2005;48(3):365-77
33 Fayers PM, Hopwood P, Harvey A, Girling DJ, Machin D, Stephens R. Quality of life assessment in clinical trials--guidelines and a checklist for protocol writers: the U.K. Medical Research Council experience. MRC Cancer Trials Office. Eur J Cancer. 1997;33(1):20-8.
34 Flores SA, Crepaz N. Quality of study methods in individual- and group-level HIV intervention research: CRITICAL reporting elements. AIDS Education & Prevention. 2004;16(4):341-52.
35 Fowler FJ Jr. Data collection methods. (1996) In Quality of Life and Pharmacoeconomics in clinical trials. Ed. B. Spilker. Lippencott-Raven, New York
36 Friedman LM, Furberg CD, DeMets DL (1998): Fundamentals of Clinical Trials. New York: Springer-Verlag.
37 Ganz PA, Gotay CC. Use of patient-reported outcomes in phase III cancer treatment trials: lessons learned and future directions. J Clin Oncol. 2007;25(32):5063-9
38 Ganz PA, Haskell CM, Figlin RA, La Soto N, Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index--Cancer. Cancer. 1988;61(4):849-56.
39 Gates S, Williams MA, Withers E, Williamson E, Mt-Isa S, Lamb SE. Does a monetary incentive improve the response to a postal questionnaire in a randomised controlled trial? The MINT incentive study. Trials. 2009;10:44.
40 Gheorghe A, Kyte D, Calvert M. The need for increased harmonisation of clinical trials and economic evaluations. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):171-3
41 Gotay CC, Lipscomb J, Snyder CF. Reflections on Findings of the Cancer Outcomes Measurement Working Group: Moving to the Next Phase. Journal of the National Cancer Institute 2005; 97: 1568-1574.
42 Groenvold M. Methodological issues in the assessment of health-related quality of life in palliative care trials. Acta Anaesthesiol Scand. 1999;43(9):948-53

43 Hahn EA, Webster KA, Cella D, Fairclough DL. Missing data in quality of life research in Eastern Cooperative Oncology Group (ECOG) clinical trials: problems and solutions. Stat Med. 1998;17(5-7):547-59

44 Hallum-Montes, R., L. Senter, et al. (2014). "Improving Completion Rates for Client Intake Forms through Audio Computer-Assisted Self-Interview (ACASI): Results from a Pilot Study with the Avon Breast Health Outreach Program." Journal for Healthcare Quality: Promoting Excellence in Healthcare 36(6): 47-53.

45 Hanscom B, Lurie JD, Homa K, Weinstein JN. Computerized questionnaires and the quality of survey data. Spine J. 2002;27(16):1797-801.

46 Hao Y. Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges. Expert rev. 2010;10(4):407-20

47 Hayden KA, Moinpour CM, Metch B, Feigl P, O'Bryan RM, Green S, et al. Pitfalls in quality-of-life assessment: lessons from a Southwest Oncology Group breast cancer clinical trial. Oncol Nurs Forum. 1993;20(9):1415-9.

48 Hellard ME, Sinclair MI, Forbes AB, Fairley CK. Methods used to maintain a high level of participant involvement in a clinical trial. Journal of Epidemiology & Community Health. 2001;55(5):348-51.

49 Hewitt CE, Kumaravel B, Dumville JC, Torgerson DJ. Assessing the impact of attrition in randomized controlled trials. J Clin Epidemiol. 2010;63(11):1264-70.

50 Hjermstad MJ, Lie HC, Caraceni A, Currow DC, Fainsinger RL, Gundersen OE, et al. Computer-based symptom assessment is feasible in patients with advanced cancer: results from an international multicenter study, the EPCRC-CSA. J Pain Symptom Manage. 2012;44(5):639-54.

51 Hopwood P, Harvey A, Davies J, Stephens RJ, Girling DJ, Gibson D, et al. Survey of the administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. Eur J Cancer. 1998;34(1):49-57.

52 Hopwood P. Quality of life assessment in chemotherapy trials for non-small cell lung cancer: are theory and practice significantly different? Semin Oncol. 1996;23(5 Suppl 10):60-4

53 Huntington JL, Dueck A. Handling missing data. Curr Probl Cancer. 2005;29(6):317-25.

54 Hurny C, Bernhard J, Joss R, Willems Y, Cavalli F, Kiser J, et al. Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer--a lesson from the real world--the Swiss Group for Clinical Cancer Research SAKK. Ann Oncol. 1992;3(10):825-31.

55 Jansen ME, Kollbaum PS, McKay FD, Rickert ME. Factors influencing the electronic capture of patient-reported contact lens performance data. Cont Lens Anterior Eye. 2013;36(3):130-5.

56 Jordhoy MS, Kaasa S, Fayers P, Ovreness T, Underland G, Ahlner-Elmqvist M. Challenges in palliative care research; recruitment, attrition and compliance: experience from a randomized controlled trial. Palliat Med. 1999;13(4):299-310.

57 Kaasa S, Hjermstad MJ, Jordhoy MS, Wisloff F, Loge JH. Compliance in quality of life data: a Norwegian experience. Stat Med. 1998;17(5-7):623-32

58 Kaasa S, Loge JH. Quality-of-life assessment in palliative care. The Lancet Oncology. 2002;3(3):175-82.

59 Kaasa S. Measurement of quality of life in clinical trials. Oncology. 1992;49(4):289-94.

60 Kiebert GM, Curran D, Aaronson NK. Quality of life as an endpoint in EORTC clinical trials. European Organization for Research and Treatment for Cancer. Stat Med. 1998;17(5-7):561-9.

61 Kim J, Lonner JH, Nelson CL, Lotke PA. Response bias: effect on outcomes evaluation by mail surveys after total knee arthroplasty. J Bone Joint Surg Am. 2004;86-A(1):15-21

62 Klee M, Groenvold M, Machin D. Using data from studies of health-related quality of life to describe clinical issues examples from a longitudinal study of patients with advanced stages of cervical cancer. Qual Life Res. 1999;8(8):733-42

63 Kleinpell-Nowell, R. (2000). "Strategies for assessing outcomes in the elderly in acute care." AACN Clinical Issues: Advanced Practice in Acute & Critical Care 11(3): 442-452.

64 Kyte DG, Draper H, Ives J, Liles C, Gheorghe A, Calvert M. Patient reported outcomes (PROs) in clinical trials: is 'in-trial' guidance lacking? a systematic review. PLoS ONE. 2013;8(4):e60684

65 Land SR, Ritter MW, Costantino JP, Julian TB, Cronin WM, Haile SR, et al. Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches. J Clin Oncol. 2007;25(32):5113-20.

66 Larkin ME, Lorenzi GM, Bayless M, Cleary PA, Barnie A, Golden E, et al. Evolution of the study coordinator role: the 28-year experience in Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC). Clin Trials. 2012;9(4):418-25.

67 Lee CW, Chi KN. The standard of reporting of health-related quality of life in clinical cancer trials. J Clin Epidemiol. 2000;53(5):451-8.

68 Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355-60.

69 Little, Cohen, Dickersin, et al. The design and conduct of clinical trials to limit missing dataStatist. Med. 2012, 31, 3433–3443

70 Luo X, Cappelleri JC. A Practical Guide on Incorporating and Evaluating Patient-Reported Outcomes in Clinical Trials. Clinical Research and Regulatory Affairs. 2008;25(4):197-211.

71 Macefield RC, Avery KN, Blazeby JM. Integration of clinical and patient-reported outcomes in surgical oncology. Br J Surg. 2013;100(1):28-37.

72 Machin D, Weeden S. Suggestions for the presentation of quality of life data from clinical trials. Stat Med. 1998;17(5-7):711-24

73 McMillan SC, Weitzner MA. Methodologic issues in collecting data from debilitated patients with cancer near the end of life. Oncol Nurs Forum. 2003;30(1):123-9. Epub 2003/01/08.

74 Meyer KB, Clayton KA. Measurement and analysis of patient-reported outcomes. Methods Mol Biol. 2009;473:155-69.

75 Meyers, K., A. Webb, et al. (2003). "What does it take to retain substance-abusing adolescents in research protocols? Delineation of effort required, strategies undertaken, costs incurred, and 6-month post-treatment differences by retention difficulty." Drug & Alcohol Dependence 69(1): 73-85.

76 Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL, Crowley J. Quality of Life End Points in Cancer Clinical Trials: Review and Recommendations. J Natl Cancer Inst. 1989;81(7):485-96

77 Moinpour CM, Hayden KA, Thompson IM, Feigl P, Metch B. Quality of life assessment in Southwest Oncology Group trials. Oncology (Williston). 1990;4(5):79-84, 9; discussion 104.

78 Moinpour CM, Lovato LC. Ensuring the quality of quality of life data: the Southwest Oncology Group experience. Stat Med. 1998;17(5-7):641-51. Epub 1998/04/29.

79 Movsas B, Scott C. Quality-of-life trials in lung cancer: past achievements and future challenges. Hematol Oncol Clin North Am. 2004;18(1):161-86.

80 Movsas B. Quality of life in oncology trials: a clinical guide. Semin Radiat Oncol. 2003;13(3):235-47.

81 Moynihan C. Patient 'non-compliance' and 'missing data' in quality of life research: where does the problem lie? Eur J Cancer. 1998;34(1):9-11

82 Muller-Buhl U, Franke B, Hermann K, Engeser P. Lowering missing item values in quality-of-life questionnaires: an interventional study. Int J Public Health. 2011;56(1):63-9

83 Newgard, C. D. and J. S. Haukoos (2010). ""Measuring Quality With Missing Data: The Invisible Threat to National Quality Initiatives."" Academic Emergency Medicine 17(10): 1130-1133.

84 Noyez L, de Jager MJ, Markou AL. Quality of life after cardiac surgery: underresearched research. Interact Cardiovasc Thorac Surg. 2011;13(5):511-4.

85 Osoba D, Bezjak A, Brundage M, Pater J. Evaluating health-related quality of life in cancer clinical trials: the National Cancer Institute of Canada Clinical Trials Group experience. Value Health. 2007;10 Suppl 2:S138-45. Epub 2007/11/13.

86 Osoba D, Dancey J, Zee B, Myles J, Pater J. Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group. J Natl Cancer Inst Monogr. 1996;Monographs.(20):107-11. Epub 1996/01/01.
87 Osoba D. The Quality of Life Committee of the Clinical Trials Group of the National Cancer Institute of Canada: organization and functions. Qual Life Res. 1992;1(3):211-8.
88 Peruselli C, Paci E, Franceschi P, Legori T, Mannucci F. Outcome evaluation in a home palliative care service. J Pain Symptom Manage. 1997;13(3):158-65
89 Pijls-Johannesma MC, Pijpe A, Kempen GI, Lambin P, Dagnelie PC. Health related quality of life assessment instruments: a prospective study on preference and acceptability among cancer patients referred for radiotherapy. Eur J Cancer. 2005;41(15):2250-6.
90 Poulter K (1997) The administration of quality of life questionnaires within clinical trials. Good Clinical Practice Journal 4: 22-25
91 Poy E. Objectives of QC systems and QA function in clinical research. Qual Assur. 1993;2(4):326-31.
92 Repetto L, Comandini D, Mammoliti S. Life expectancy, comorbidity and quality of life: the treatment equation in the older cancer patients. Crit Rev Oncol Hematol. 2001;37(2):147-52.
93 Revicki D. Reporting analyses from clinical trials. In Assessing Quality of Life in Clinical Trials: 2nd edition Analysis and Interpretation. Peter Fayers and Ron Hays (eds). Oxford University Press, 2005
94 Revicki D. Reporting analyses from clinical trials. In Fayers P, Hays R (eds): Assessing Quality of Life in Clinical Trials: Analysis and Interpretation. , 2nd Edition. Oxford University Press 2005.
95 Revicki DA, Erickson PA, Sloan JA et al. Interpreting and Reporting Results Based on Patient-Reported Outcomes. Value in Health 2007; 10, Supplement 2: S116-S124.
96 Rock EP, Scott JA, Kennedy DL, Sridhara R, Pazdur R, Burke LB. Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products. J Natl Cancer Inst Monogr. 2007;Monographs.(37):27-30
97 Sadura A, Pater J, Osoba D, Levine M, Palmer M, Bennett K. Quality-of-life assessment: patient compliance with questionnaire completion. J Natl Cancer Inst. 1992;84(13):1023-6.
98 Scott RB, Farmer E, Smiton A, Tovey C, Clarke M, Carpenter K. Methodology of neuropsychological research in multicentre randomized clinical trials: a model derived from the International Subarachnoid Aneurysm Trial. Clin Trials. 2004;1(1):31-9.
99 Senturia YD, McNiff Mortimer K, Baker D, Gergen P, Mitchell H, Joseph C, et al. Successful Techniques for Retention of Study Participants in an Inner-City Population. Control Clin Trials. 1998;19(6):544-54.
100 Shelby-James TM, Hardy J, Agar M et al. Designing and conducting randomized controlled trials in palliative care: A summary of discussions from the 2010 clinical research forum of the Australian Palliative Care Clinical Studies Collaborative. Palliative Medicine 2012; 26: 1042-1047.
101 Sherman DW, McSherry, CB Parkas V, Ye XY, Calabrese M, Gatto M. (2005) Recruitment and retention in a longitudinal palliative care study. Applied Nursing Research 18:167-177
102 Siddiqui F, Liu AK, Watkins-Bruner D, Movsas B. Patient-reported outcomes and survivorship in radiation oncology: overcoming the cons. J Clin Oncol. 2014;32(26):2920-7
103 Simes RJ, Greatorex V, Gebski VJ. Practical approaches to minimize problems with missing quality of life data. Stat Med. 1998;17(5-7):725-37.
104 Sloan et al 2007 Analysis and Interpretation of Results Based on Patient-Reported Outcomes. Value in Health 10(2) S106–S115
105 Sprague S, Leece P, Bhandari M, Tornetta Iii P, Schemitsch E, Swiontkowski MF. Limiting loss to follow-up in a multicenter randomized trial in orthopedic surgery. Control Clin Trials. 2003;24(6):719-25.
106 Sprangers MAG, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA. Symposium on quality of life in cancer patients. Assessing meaningful change in quality of life over time: a users' guide for clinicians. Mayo Clinic Proceedings. 2002;77(6):561-71.
107 Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. Qual Life Res. 1996;5(5):496-502.

108 Steinhauser KE, Clipp EC, Hays JC et al. Identifying, recruiting, and retaining seriously-ill patients and their caregivers in longitudinal research. Palliative Medicine 2006; 20: 745-754.
109 Stewart AL. Conceptual and methodologic issues in defining quality of life: state of the art. Progress in Cardiovascular Nursing. 1992;7(1):3-11.
110 Tang ST, McCorkle R. Appropriate time frames for data collection in quality of life research among cancer patients at the end of life. Qual Life Res. 2002;11(2):145-55
111 Taphoorn MJ, Sizoo EM, Bottomley A. Review on quality of life issues in patients with primary brain tumors. Oncologist. 2010;15(6):618-26
112 Vantongelen K, Rotmensz N, van der Schueren E. Quality control of validity of data collected in clinical trials. EORTC Study Group on Data Management (SGDM). Eur J Cancer Clin Oncol. 1989;25(8):1241-7
113 Walker M, Brown J, Brown K, Gregor A, Whittle IR, Grant R. Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma. J Neurooncol. 2003;63(2):179-86.
114 Wilcox S, Shumaker SA, Bowen DJ, Naughton MJ, Rosal MC, Ludlam SE, et al. Promoting Adherence and Retention to Clinical Trials in Special Populations: A Women's Health Initiative Workshop. Control Clin Trials. 2001;22(3):279-89.
115 Wisniewski SR, Leon AC, Otto MW, Trivedi MH. Prevention of missing data in clinical research studies. Biol Psychiatry. 2006;59(11):997-1000.
116 Young T, Maher J. Collecting quality of life data in EORTC clinical trials--what happens in practice? Psychooncology. 1999;8(3):260-3.
117 Young, T., de Haes, H., Curran, D., Fayers, P. and Brandberg, Y. (on behalf of EORTC Quality of Life Study Group) (1999) Guidelines for Assessing Quality of Life in EORTC Clinical Trials. Brussels: EORTC.